|(2S,3R,4R,5S,6R)-2-(4-氯-3-(4-(2-环丙氧基乙氧基)苄基)苯基)-6-(羟甲基)四氢-2H-吡喃-3,4,5-三醇|CsnPharm

CAS No.: 1118567-05-7

(2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol Catalog No. CSN17473

Synonyms: EGT-0001442;THR-1442;Bexagliflozin

Bexagliflozin is an inhibitor of SGLT2 with IC50 value of 2 nM.

规格	价格	促销价格	库存	数量

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

加入购物车大规格询价

加入收藏

产品咨询

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

纯度 & 质量文件批次:

靶点选择性

生物活性

实验方案

技术信息

生物活性

靶点 SGLT2

IC50:2nM SGLT1

IC50:5.6μM
描述Bexagliflozin is a potent and selective SGLT2 inhibitor with IC50 value of 5.6 μM /2 nM in SGLT1 /SGLT2 respectively.
临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT02956044	Type2 Diabetes Mellitus	Phase 1	Completed	-	United States, Indiana ... more >> Clinical Research Site Evansville, Indiana, United States, 47710 Collapse <<
NCT03514641	Essential Hypertension	Phase 2 Phase 3	Completed	-	-
NCT03296800	Type 2 Diabetes Mellitus	Phase 1	Completed	-	United States, Florida ... more >> Covance Clinical Research Unit Daytona Beach, Florida, United States, 32117 Collapse <<

实验方案

计算器摩尔计算器总药量计算器工作液计算器
储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 2.1508 mL
- 10.7542 mL
- 21.5083 mL
- 5 mM
- 0.4302 mL
- 2.1508 mL
- 4.3017 mL
- 10 mM
- 0.2151 mL
- 1.0754 mL
- 2.1508 mL

技术信息

CAS号

1118567-05-7

储存条件

粉末: Sealed in dry,Store in freezer, under -20°C

液体: -20°C:3-6 月 -80°C:12月

分子式

C24H29ClO7

运输

蓝冰

分子量

464.94

别名

EGT-0001442;THR-1442;Bexagliflozin

溶解度

DMSO	98.0 mg/mL (210.8 mM)

动物实验配方

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT02956044	Type2 Diabetes Mellitus	Phase 1	Completed	-	United States, Indiana ... more >> Clinical Research Site Evansville, Indiana, United States, 47710 Collapse <<
NCT03514641	Essential Hypertension	Phase 2 Phase 3	Completed	-	-
NCT03296800	Type 2 Diabetes Mellitus	Phase 1	Completed	-	United States, Florida ... more >> Covance Clinical Research Unit Daytona Beach, Florida, United States, 32117 Collapse <<
NCT02769481	Type 2 Diabetes Mellitus	Phase 3	Active, not recruiting	December 2019	-
NCT03167411	Type2 Diabetes Mellitus	Phase 1	Completed	-	United States, Indiana ... more >> Clinical Research Site Evansville, Indiana, United States, 47710 Collapse <<
NCT03197324	Type2 Diabetes Mellitus	Phase 1	Completed	-	United States, Florida ... more >> Covance CRU Daytona Beach, Florida, United States, 32117 Collapse <<
NCT03259789	Type2 Diabetes Mellitus	Phase 3	Active, not recruiting	January 2019	-
NCT02558296	Type 2 Diabetes Mellitus	Phase 3	Active, not recruiting	April 2019	-
NCT02836873	Type 2 Diabetes Mellitus	Phase 3	Completed	-	-
NCT03115112	Type 2 Diabetes Mellitus	Phase 3	Completed	-	-
NCT02390050	Diabetes Mellitus, Type 2	Phase 2 Phase 3	Completed	-	-
NCT02820298	Type 2 Diabetes Mellitus	Phase 1	Completed	-	United States, Colorado ... more >> Denver Clinical Research Unit Lakewood, Colorado, United States, 80228 Collapse <<
NCT03417076	Type 2 Diabetes Mellitus	Phase 1	Withdrawn(Sponsor decision to ... more >>not initiate study due to sufficient bioavailability information) Collapse <<	September 16, 2018	United States, Wisconsin ... more >> Clinical Research Site Madison, Wisconsin, United States, 53704 Collapse <<
NCT03557658	Type2 Diabetes Mellitus	Phase 1	Recruiting	December 20, 2018	United States, Massachusetts ... more >> Clinical Research Site 1 Recruiting Boston, Massachusetts, United States, 02114 United States, Minnesota Clinical Research Site 2 Recruiting Saint Paul, Minnesota, United States, 55114 Collapse <<
NCT02715258	Type 2 Diabetes Mellitus	Phase 3	Completed	-	United States, California ... more >> Research Site Canoga Park, California, United States, 91303 Research Site Chino, California, United States, 91710 Research Site Huntington Park, California, United States, 90255 Research Site Los Angeles, California, United States, 90057 Research Site San Diego, California, United States, 92103 United States, Florida Research Site Fort Lauderdale, Florida, United States, 33316 Research Site Hialeah, Florida, United States, 33012 Research Site Miami Lakes, Florida, United States, 33016 Research Site Orlando, Florida, United States, 32806 Research Site Port Orange, Florida, United States, 32127 United States, New Jersey Research Site Trenton, New Jersey, United States, 08611 United States, North Carolina Research Site Calabash, North Carolina, United States, 28467 Research Site Morehead City, North Carolina, United States, 28557 United States, Ohio Research Site Munroe Falls, Ohio, United States, 44262 United States, Oregon Research Site Portland, Oregon, United States, 97239 United States, South Carolina Research Site North Myrtle Beach, South Carolina, United States, 29582 United States, Texas Research Site DeSoto, Texas, United States, 75115 Research Site Fort Worth, Texas, United States, 76164 Canada, British Columbia Research Site Vancouver, British Columbia, Canada, V6J 1S3 Canada, Ontario Research Site Newmarket, Ontario, Canada, L3Y 5G8 Research Site 2 Toronto, Ontario, Canada, M9V 4B4 Research Site 1 Toronto, Ontario, Canada, M9W 4L6 Canada, Quebec Research Site Pointe-Claire, Quebec, Canada, H9R 4S3 Collapse <<

靶点	Description	IC50
SGLT2		IC50:2nM
SGLT1		IC50:5.6μM

(2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol Catalog No. CSN17473

靶点选择性

请登录您的专属账户

确认信息